– IRELAND, Dublin – Nabriva Therapeutics plc (NASDAQ: NBRV) today announced the appointments of Dr. Mark Corrigan and Lisa Dalton to its Board of Directors.
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
“We are excited to welcome Mark back to the Nabriva Board and are absolutely delighted to welcome Lisa to the Nabriva Board. Mark’s extensive experience in the industry from both a scientific and executive level brings a wealth of experience and knowledge to the Board. Likewise, the addition of Lisa’s extensive experience in human resources and executive management will be an invaluable asset to the organization.” said Board Chairman, Dan Burgess.
In addition, Dr. George Talbot has notified his decision not to stand for re-election to the Board of Directors.
Dan Burgess added, “On behalf of the entire Board, I would also like to thank Dr. Talbot for his efforts, input, and many contributions to Nabriva over the past 12 years.”
About Mark Corrigan
Dr. Corrigan is a highly successful pharmaceutical executive with 30 years of industry experience, including roles as CEO, Global R&D Lead, and serving on the Boards of other biotech companies. Dr.
Dr. Corrigan currently serves as Chairman of the Board of Exacis Therapeutics, as well as Co-Founder and Board Member of Tremeau Pharmaceuticals, Inc.
Dr. Corrigan holds a Bachelor of Science from the University of Virginia, as well as an MD from the University of Virginia School of Medicine.
About Lisa Dalton
Ms. Dalton is a highly experienced pharmaceutical and biotechnology executive with over 25 years in the industry. Currently, Ms. Dalton serves as Chief People Officer at Spark Therapeutics, Inc. Before joining Spark, Ms. Dalton spent 10 years at Shire plc in various leadership roles within the Human Resources function.
Ms. Dalton holds a Bachelor of Arts degree in Psychology from The Pennsylvania State University and a Master of Business Administration in Organizational Behavior Studies from Rutgers University.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA, the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia. Nabriva Therapeutics is also developing CONTEPO for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections, including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO in the United States and certain of its territories.
For more information: https://www.nabriva.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.